Ultragenyx Pharmaceutical (MEX:RARE) PEG Ratio: N/A (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RARE Ultragenyx Pharmaceutical Inc MEX:RARE
70 GF Score
Price MXN1,150.56
GF Value MXN1,699.44
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Ultragenyx Pharmaceutical's PE Ratio without NRI is 0.00. Ultragenyx Pharmaceutical's 5-Year EBITDA growth rate is -8.80%. Therefore, Ultragenyx Pharmaceutical's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Ultragenyx Pharmaceutical's PEG Ratio or its related term are showing as below:



MEX:RARE's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.97
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Ultragenyx Pharmaceutical  (MEX:RARE) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Ultragenyx Pharmaceutical PEG Ratio Related Terms


Ultragenyx Pharmaceutical PEG Ratio Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical PEG Ratio Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ultragenyx Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:RARE vs VERA, IRON, QURE: PEG Ratio Comparison

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's PEG Ratio falls into.


MEX:RARE
70GF Score
Ultragenyx Pharmaceutical Inc MEX:RARE
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ultragenyx Pharmaceutical PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Ultragenyx Pharmaceutical's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-8.80
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of MXN1,150.56 is trading 32.3% below its estimated GF Value™ of MXN1,699.44.

Key valuation signals for MEX:RARE:

  • PEG Ratio: N/A
  • GF Value™: MXN1,699.44 vs. price of MXN1,150.56 (32.3% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
70GF Score

Get the complete analysis for MEX:RARE

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.56
Price
MXN1,699.44
GF Value